Bristol-Myers Squibb Co. (BMY) PT Lowered to $41 at Barclays
Tweet
Share
E-mailGet Alerts BMY Hot Sheet
Price: $63.83 -1.27%
Rating Summary:
12 Buy, 22 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
12 Buy, 22 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Barclays analyst Carter Gould lowered the price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $41.00 (from $43.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- FDA grants accelerated approval to Bristol Myers Squibb's Zenbexus
- Va Tech Wabag Ltd. (VATW:IN) PT Raised to INR2,410 at ICICI Securities
- Atrium Therapeutics receives $15M milestone from Bristol Myers Squibb
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
